

I hereby certify that this correspondence is being transmitted via the Office electronic filing system to the U.S. Patent and Trademark Office, on the date shown below.

Dated: January 7, 2008

Signature: /Mark D. Russett/  
Mark D. Russett, Reg. No. 41,281

Docket No.: 61385(72021)  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Kevin J. Hodgetts et al.

Application No.: 10/591,383

Confirmation No.: 8106

Filed: September 1, 2006

Art Unit: 1621

For: HETEROALKYL-SUBSTITUTED  
BIPHENYL-4-CARBOXYLIC ACID  
ARYLAMIDE ANALOGUES

Examiner: S. Kumar

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Applicants are aware of certain documents, cited in a Supplementary European Search Report mailed October 2, 2007, during the prosecution of European Patent Office (EPO) Patent Application 05724513.6, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97 hereby submit(s) these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of the Supplementary European Search Report and each document required under 37 CFR 1.98(a)(2) cited thereon are enclosed.

Applicants note that reference D4 (WO00/40239) of the Supplementary European Search Report has previously been made of record in the subject application.

As to reference D5 (WO2004/056774) of the Supplementary European Search Report, Applicants also note that the U.S. equivalent (U.S. Patent Publication No. 2006-0100245) has previously been made of record in the subject application.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 61385(72021).

Dated: January 7, 2008

Respectfully submitted,

By /Mark D. Russett/  
Mark D. Russett, Registration No.: 41,281  
EDWARDS ANGELL PALMER & DODGE LLP  
P.O. Box 55874  
Boston, Massachusetts 02205  
(617) 239-0100  
Attorneys/Agents For Applicants